Leading Neurologists Discuss Unmet Needs in Mid- to Late-stage Parkinson’s Disease Patients

Jan 12, 2016, 08:13 ET from touchNEUROLOGY.com

LONDON, January 12, 2016 /PRNewswire/ --

European Neurological Review, the peer-reviewed journal, has published the proceedings of a satellite symposium held at the first EAN Congress in Berlin in June 2015 which assesses factors involved in the progression of Parkinson's disease and highlights currently unmet needs in mid- to late-stage patients.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )
In early-stage Parkinson's disease (PD), dopaminergic treatment is highly effective in controlling motor symptoms. However, as the disease progresses, other symptoms and comorbidities need to be addressed, such as suboptimal motor control, emerging motor complications (e.g. nocturnal and early-morning akinesia/tremor, early wearing-off and dyskinesia), emerging levodopa-resistant motor symptoms, increasing non-motor symptoms and treatment of non-dopaminergic symptoms. Despite these unmet needs, no new therapies for PD have been introduced into routine clinical practice over the past 10 years. Safinamide is a new oral therapy that has both dopaminergic and non-dopaminergic mechanisms of action. In phase III clinical trials, safinamide has demonstrated significant clinical benefits in patients with mid- to late-stage PD experiencing motor fluctuations as an add-on therapy to levodopa and other PD medication versus those treated only on an optimised PD therapy. This includes improvements in daily ON time, improvements in motor function and beneficial effects on dyskinesia that have been studied in patients for up to 2 years. Safinamide is well tolerated, and it is a new and unique agent in the armamentarium of treatments for patients with mid- to late-stage PD experiencing motor fluctuations.

The full peer-reviewed, open-access article is available here:

href="http://www.touchophthalmology.com/articles/low-energy-stereotactic-radiotherapy-treatment-exudative-age-related-macular-degeneration" rel="nofollow">http://doi.org/10.17925/ENR.2015.10.02.182

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishesEuropean Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.


Providing practical opinion to support best practice for busy healthcare professionals.

For inquires please contact:
Carla Denaro - Managing Editor
T: +44(0)207-193-6093